Synthetic peptide analogs of tissue factor and factor VII which inhibit factor Xa formation by the tissue factor/factor VIIa complex. 1996

H F Rønning, and U C Risøen, and L Orning, and K Sletten, and K S Sakariassen
Department of Biochemistry/Biotechnology Centre, University of Oslo, Norway.

Factor VII (FVII) and tissue factor (TF) form a binary complex which initiates the extrinsic pathway of the blood coagulation cascade. The infrequent tripeptide motif Trp-Lys-Ser (WKS) is found three times in TF. It has been suggested that the motif is involved in binding of TF to FVII(a). Also. Lys165 and Lys166 of TF have been reported to be important for factor X activation. To elucidate the molecular interactions between TF and FVIIa, and the interactions between the binary complex and FX, we examined the inhibitory effect of synthetic TF and FVII peptide analogs. One- and two-stage chromogenic assays were employed, as well as one-stage coagulation assay. The peptide analogs of TF possessed the WKS motif, the double lysine residues or other regions of TF. Synthetic peptides of FVII encompassing sequences of the FVII285-305 region were included for comparative purposes. TF154-167 and FVII300-305 significantly inhibited both FX activation and plasma coagulation. FVII285-294 acted synergistically, increasing that effect observed by FVII300-305 on FX activation. However, TF163-175 possessing the double lysine residues did not inhibit FX activation, indicating that inhibition of FXa formation and coagulation by TF154-167 is due to the region 154-162 of TF. None of the peptides, including the WKS tripeptide, interfered with the FVIIa activity of the TF/FVIIa complex. Thus, the results do not suggest that the WKS motifs are necessary for binding of TF to FVIIa but that the third WKS motif may be of importance for the activation of FX.

UI MeSH Term Description Entries
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D005167 Factor VII Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the activation of factor X to factor Xa. Coagulation Factor VII,Proconvertin,Stable Factor,Blood Coagulation Factor VII,Factor 7,Factor Seven,Factor VII, Coagulation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013925 Thromboplastin Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation. Antigens, CD142,CD142 Antigens,Coagulation Factor III,Factor III,Tissue Factor,Tissue Thromboplastin,Blood Coagulation Factor III,Coagulin,Glomerular Procoagulant Activity,Prothrombinase,Tissue Factor Procoagulant,Urothromboplastin,Activity, Glomerular Procoagulant,Factor III, Coagulation,Procoagulant Activity, Glomerular,Procoagulant, Tissue Factor,Thromboplastin, Tissue
D015942 Factor VIIa Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation. Coagulation Factor VIIa,Factor VII, Activated,Blood Coagulation Factor VII, Activated,Factor 7A,Factor Seven A,Activated Factor VII,Factor VIIa, Coagulation
D065427 Factor Xa Inhibitors Endogenous factors and drugs that inhibit or block the activity of FACTOR XA. Direct Factor Xa Inhibitor,Direct-Acting Oral Anticoagulant,Direct-Acting Oral Anticoagulants,Factor Xa Inhibitor,Direct Factor Xa Inhibitors,Anticoagulant, Direct-Acting Oral,Anticoagulants, Direct-Acting Oral,Direct Acting Oral Anticoagulant,Direct Acting Oral Anticoagulants,Inhibitor, Factor Xa,Oral Anticoagulant, Direct-Acting,Oral Anticoagulants, Direct-Acting,Xa Inhibitor, Factor

Related Publications

H F Rønning, and U C Risøen, and L Orning, and K Sletten, and K S Sakariassen
October 2017, Blood,
H F Rønning, and U C Risøen, and L Orning, and K Sletten, and K S Sakariassen
August 2006, Thrombosis and haemostasis,
H F Rønning, and U C Risøen, and L Orning, and K Sletten, and K S Sakariassen
July 2008, Thrombosis and haemostasis,
H F Rønning, and U C Risøen, and L Orning, and K Sletten, and K S Sakariassen
June 2003, European journal of biochemistry,
H F Rønning, and U C Risøen, and L Orning, and K Sletten, and K S Sakariassen
June 2007, FEBS letters,
H F Rønning, and U C Risøen, and L Orning, and K Sletten, and K S Sakariassen
January 2004, Journal of thrombosis and haemostasis : JTH,
H F Rønning, and U C Risøen, and L Orning, and K Sletten, and K S Sakariassen
November 2003, Proteins,
H F Rønning, and U C Risøen, and L Orning, and K Sletten, and K S Sakariassen
May 1987, Thrombosis research,
H F Rønning, and U C Risøen, and L Orning, and K Sletten, and K S Sakariassen
August 1993, The Journal of biological chemistry,
H F Rønning, and U C Risøen, and L Orning, and K Sletten, and K S Sakariassen
July 1993, Biochemistry,
Copied contents to your clipboard!